Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study

This study represents the first real-world analysis comparing the adverse event profiles of triplet therapy and docetaxel-based therapy in Japanese patients with mCSPC, as well as docetaxel-based therapy in those with mCRPC. No significant difference in severe AEs was observed between the therapies. Primary prophylaxis with G-CSF proved critical in reducing severe neutropenia and FN, underscoring its importance in enhancing the safety and efficacy of docetaxel-based therapies.

Authors

Institutions

Publication Details

Journal
Prostate International
Published
2024-11-22
DOI
https://doi.org/10.1016/j.prnil.2024.11.003
Citations
4
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
1.68
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study

Kenichi Hata, Taro Igarashi, Hiroki Yamada, Masaki Hashimoto et al.
4 citations
Prostate International
Prostate Cancer Treatment and Research
1.68
article

Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study

Kenichi Hata, Taro Igarashi, Hiroki Yamada, Masaki Hashimoto, Fumihiko Urabe, Kosuke Iwatani, Wataru Fukuokaya, Jun Miki, Masaya Murakami, Takafumi Yanagisawa, Kojiro Tashiro, Shuhei Hara, Shunsuke Tsuzuki, Yu Imai, Mahito Atsuta, Hidetsugu Takahashi, Brendan A. Yanada, Takahiro Kimura, Hirokazu Kagawa, Toshihiro Yamamoto
article en
4 citations

Abstract

This study represents the first real-world analysis comparing the adverse event profiles of triplet therapy and docetaxel-based therapy in Japanese patients with mCSPC, as well as docetaxel-based therapy in those with mCRPC. No significant difference in severe AEs was observed between the therapies. Primary prophylaxis with G-CSF proved critical in reducing severe neutropenia and FN, underscoring its importance in enhancing the safety and efficacy of docetaxel-based therapies.

Prostate InternationalVol. 13(1)
Jikei University School of Medicine (JP), The University of Melbourne (AU), Katsushika Medical Center (JP), The Jikei University Hospital (JP), Fujieda Municipal General Hospital (JP), Jikei University Kashiwa hospital (JP)
Good health and well-being
Openalex Percentile: Top 14%
Prostate Cancer Treatment and Research
1.68
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.